Last reviewed · How we verify
Clonidine Pill
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD), Opioid withdrawal.
At a glance
| Generic name | Clonidine Pill |
|---|---|
| Also known as | On-Drug, Clonidine |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, particularly in the locus coeruleus, which decreases the release of norepinephrine and reduces overall sympathetic outflow. This leads to decreased heart rate, blood pressure, and peripheral vascular resistance. The drug also has peripheral alpha-2 agonist effects that contribute to its antihypertensive action.
Approved indications
- Hypertension
- Attention-deficit/hyperactivity disorder (ADHD)
- Opioid withdrawal
- Menopausal hot flashes
Common side effects
- Dry mouth
- Drowsiness
- Dizziness
- Constipation
- Sedation
- Headache
- Rebound hypertension (upon discontinuation)
Key clinical trials
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Repurposing Low-Dose Clonidine for PTSD in Veterans (PHASE3)
- Mitigating the Pro-inflammatory Phenotype of Obesity (PHASE1)
- Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System (PHASE4)
- Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain (PHASE3)
- The Role of Stress Neuromodulators in Decision Making Under Risk (Part II) (NA)
- Clonidine is Better Than Zopiclone for Insomnia Treatment in Chronic Pain Patients
- PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |